DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
DEXCOM INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$85.98−0.06 (-0.07%)
Close on Oct 19, 2026
- Market cap
- $33.54B
- P/E (TTM)
- 34.1
- Dividend yield
- –
Dexcom statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Dexcom | Industry median |
|---|---|---|
| Market Cap | $32.45B | $229.23M |
| Enterprise Value | $31.34B | $194.73M |
| PE Ratio | 34.12 | 33.41 |
| PS Ratio | 6.53 | 3.14 |
| PB Ratio | 12.38 | 3.19 |
| P/TBV Ratio | 13.00 | 4.69 |
| P/FCF Ratio | 23.09 | 27.25 |
| P/OCF Ratio | 18.55 | 22.23 |
Enterprise value
| Measure | Dexcom | Industry median |
|---|---|---|
| EV / Sales | 6.31 | 2.93 |
| EV / EBITDA | 22.34 | 19.97 |
| EV / EBIT | 27.51 | 25.47 |
| EV / FCF | 22.31 | 27.85 |
Income (trailing twelve months)
| Measure | Dexcom | Industry median |
|---|---|---|
| Revenue | $4.97B | $102.39M |
| Gross Profit | $3.10B | $60.36M |
| Operating Income | $1.14B | -$4.31M |
| Pretax Income | $1.28B | -$2.26M |
| Net Income | $999.70M | -$6.57M |
| EBITDA | $1.40B | -$1.98M |
| EPS (Diluted) | $2.52 | -$0.07 |
Margins
| Measure | Dexcom | Industry median |
|---|---|---|
| Gross Margin | 62.5% | 55.1% |
| Operating Margin | 22.9% | -6.04% |
| Pretax Margin | 25.8% | -4.11% |
| Profit Margin | 20.1% | -10.5% |
| EBITDA Margin | 28.2% | -2.67% |
| FCF Margin | 28.3% | -0.30% |
Returns
| Measure | Dexcom | Industry median |
|---|---|---|
| Return on Equity (ROE) | 38.5% | -19.2% |
| Return on Assets (ROA) | 14.5% | -13.3% |
| Return on Invested Capital (ROIC) | 60.7% | -4.11% |
| Return on Capital Employed (ROCE) | 27.8% | -9.07% |
Growth
| Measure | Dexcom | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 15.5% | 8.85% |
| Net Income Growth (YoY) | 74.9% | 10.6% |
| EPS Growth (YoY) | 76.2% | 10.6% |
| FCF Growth (YoY) | 146.1% | 10.6% |
| Revenue Growth (3Y CAGR) | 17.0% | 7.08% |
| Revenue Growth (5Y CAGR) | 19.3% | 11.8% |
| EPS Growth (3Y CAGR) | 36.6% | 3.06% |
| EPS Growth (5Y CAGR) | 9.46% | 7.64% |
Balance sheet
| Measure | Dexcom | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.11B | $37.33M |
| Net Cash (Debt) | $1.11B | $3.92M |
| Net Cash Per Share | $2.93 | $0.28 |
| Equity (Book Value) | $2.62B | $57.36M |
| Book Value Per Share | $6.95 | $2.81 |
| Tangible Book Value | $2.50B | $10.71M |
| Working Capital | $1.73B | $54.64M |
Financial position
| Measure | Dexcom | Industry median |
|---|---|---|
| Current Ratio | 1.73 | 2.50 |
| Quick Ratio | 1.00 | 1.54 |
| Interest Coverage | 75.94 | -1.81 |
Cash flow (trailing twelve months)
| Measure | Dexcom | Industry median |
|---|---|---|
| Operating Cash Flow | $1.75B | -$653.46K |
| Capital Expenditures | -$343.70M | -$3.69M |
| Free Cash Flow | $1.41B | -$835.02K |
| FCF Per Share | $3.72 | -$0.02 |
Efficiency
| Measure | Dexcom | Industry median |
|---|---|---|
| Asset Turnover | 0.72 | 0.59 |
| Inventory Turnover | 2.88 | 2.21 |
| Revenue Per Employee | $447.68K | $322.75K |
| Profits Per Employee | $90.06K | -$52.11K |
| Employee Count | 11,100 | 197 |
Dividends and yields
| Measure | Dexcom | Industry median |
|---|---|---|
| Earnings Yield | 3.08% | -6.92% |
| FCF Yield | 4.33% | -0.62% |
| Buyback Yield | -0.08% | 0.78% |
| Shareholder Yield | -0.08% | 0.84% |
Shares
| Measure | Dexcom | Industry median |
|---|---|---|
| Shares Outstanding | 377,361,000 | 44,856,700 |
| Shares Change (YoY) | -2.61% | 3.35% |
| Shares Change (QoQ) | -2.20% | 0.27% |
| Float | 375,415,000 | 36,934,400 |
| Shares Held by Insiders | 0.52% | 10.6% |
| Shares Held by Institutions | 102.5% | 63.5% |
Taxes
| Measure | Dexcom | Industry median |
|---|---|---|
| Income Tax | $280.30M | $1.52M |
| Effective Tax Rate | 21.9% | 18.6% |
Scores
| Measure | Dexcom | Industry median |
|---|---|---|
| Graham Number | $19.85 | $34.37 |
| Graham Upside | -76.9% | -58.3% |
| Altman Z-Score | 7.38 | 1.95 |
| Piotroski F-Score | 8 | 5 |
| Beneish M-Score | -2.67 | -2.64 |
Calculated by StockData from Dexcom's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.